Tourbillon's Karp says Sarepta shares could surge 200 percent

LAS VEGAS (Reuters) - Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.

"If they can get to the sales levels in the next two years, this thing should be 200 percent higher," Karp said at the SkyBridge Capital SALT hedge fund conference. The company treats Duchenne muscular dystrophy which affects as many as 7,000 males. Its sales could climb to $600 million from $75 million now, said Karp, who specializes in picking stocks.

By the end of next year the stock price could hit $97, up from $36.10 now, he said. Sarepta shares climbed nearly 5 percent after Karp unveiled his pick.

(Reporting by Svea Herbst-Bayliss; Editing by Meredith Mazzilli)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
• Activist hedge fund Engine Capital has built a 1.5% stake in EPAM Systems - Reuters
• Activist Elliott Is Said To Build Stake In Deutsche Telekom - Bloomberg